In the latest quarter, 15 analysts provided ratings for Gilead Sciences GILD, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 7 | 8 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 4 | 2 | 0 | 0 |
| 2M Ago | 0 | 1 | 3 | 0 | 0 |
| 3M Ago | 0 | 1 | 3 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $84.87, a high estimate of $105.00, and a low estimate of $70.00. Witnessing a positive shift, the current average has risen by 8.81% from the previous average price target of $78.00.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Gilead Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Berens | Leerink Partners | Raises | Outperform | $96.00 | $74.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $94.00 | $85.00 |
| Aaron Gal | Bernstein | Announces | Outperform | $105.00 | - |
| Chris Schott | JP Morgan | Raises | Overweight | $100.00 | $95.00 |
| Carter Gould | Barclays | Raises | Equal-Weight | $84.00 | $76.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $100.00 | $78.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $75.00 | $74.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $70.00 | $70.00 |
| Joseph Catanzaro | Piper Sandler | Maintains | Overweight | $95.00 | $95.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $70.00 | $70.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $74.00 | $72.00 |
| Robyn Karnauskas | Truist Securities | Raises | Hold | $83.00 | $82.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $72.00 | $71.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $70.00 | $70.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $85.00 | $80.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gilead Sciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Gilead Sciences's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gilead Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Gilead Sciences analyst ratings.
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Gilead Sciences: Delving into Financials
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of 5.36% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Gilead Sciences's net margin is impressive, surpassing industry averages. With a net margin of 23.21%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.01% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 2.94%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Gilead Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.28.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
